Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

MLA

Gassiot, Susanna, et al. “Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?” Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 9, Sept. 2019, p. 585. EBSCOhost, https://doi.org/10.1016/j.clml.2019.05.020.

APA

Gassiot, S., González, Y., Morgades, M., Motlló, C., Clapés, V., Maluquer, C., Ibarra, G., Abril, L., Ribera, J.-M., & Oriol, A. (2019). Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? Clinical Lymphoma, Myeloma & Leukemia, 19(9), 585. https://doi.org/10.1016/j.clml.2019.05.020

Chicago

Gassiot, Susanna, Yolanda González, Mireia Morgades, Cristina Motlló, Victòria Clapés, Clara Maluquer, Gladys Ibarra, Laura Abril, Josep-Maria Ribera, and Albert Oriol. 2019. “Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?” Clinical Lymphoma, Myeloma & Leukemia 19 (9): 585. doi:10.1016/j.clml.2019.05.020.